Core Insights - Eton Pharmaceuticals is participating in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York, where its executive leadership will host 1x1 meetings [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3] - The company's commercial products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3]

Core Viewpoint - Eton Pharmaceuticals, Inc. will report its third quarter 2025 financial results on November 6, 2025, and will host a conference call to discuss these results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3]. - The company's commercial products include KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3]. - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3]. Investor Engagement - Management will take live questions during the conference call and will also answer emailed questions from investors [2]. - The live webcast of the conference call will be accessible on Eton's website, with an archived version available for 30 days after the event [2].

Group 1 - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX, and Nitisinone [3] - Eton has five additional product candidates in late-stage development, such as ET-600 and ZENEO hydrocortisone autoinjector [3] Group 2 - Eton's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference from September 3-5, 2025 in Boston, MA [1] - Interested parties can schedule a meeting by contacting their Wells Fargo institutional sales representative [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3] Upcoming Financial Results - Eton Pharmaceuticals will report its second quarter 2025 financial results on August 7, 2025 [1] - Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results [1] - Investors can submit questions via email during the conference call [1]

Core Insights - Eton Pharmaceuticals has received FDA acceptance for its New Drug Application (NDA) for ET-600, with a target action date set for February 25, 2026 [1] - ET-600 is a patented formulation of desmopressin oral solution, protected until 2044, aimed at treating central diabetes insipidus in pediatric patients [1][3] - The company is preparing for a potential product launch in the first quarter of 2026, addressing a significant unmet need in pediatric endocrinology [2] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products [4] - The company has five additional product candidates in late-stage development, including ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [4] - ET-600 is expected to be the only oral liquid option available for pediatric patients requiring precise dosing, as current alternatives involve cutting tablets or using unapproved suspensions [2][3]